• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年霍奇金淋巴瘤患者:来自波兰淋巴瘤研究组的回顾性多中心分析。

Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group.

机构信息

a Department of Hematology , Wroclaw Medical University , Wrocław , Poland.

b Faculty of Mathematics and Information Science , Warsaw University of Technology , Warsaw , Poland.

出版信息

Leuk Lymphoma. 2019 Feb;60(2):341-348. doi: 10.1080/10428194.2018.1482539. Epub 2018 Jul 6.

DOI:10.1080/10428194.2018.1482539
PMID:29979097
Abstract

We retrospectively analyzed long-term disease outcome of 350 elderly Hodgkin Lymphoma (eHL) patients treated with ABVD/ABVD-like regimen enrolled in the PLRG-R9 study between 2001 and 2013 in Poland. Complete remission was reported for 73% of early (ES) and 61% advanced stage (AS) patients. Nine (10%) ES and 56 (20%) AS patients have died. With the median follow-up of 36 (1-190) months, 3-year EFS and OS was 0.74 (95%CI: 0.63-0.85) and 0.90 (95%CI: 0.82-0.98) for ES; 0.51 (95%CI: 0.44-0.57), and 0.81 (95%CI: 0.75-0.86) for AS patients, respectively. For ES patients, Cox regression revealed ECOG <2 and age >70 as predictive for inferior OS and EFS. For AS patients, the most predictive for OS was the presence of cardiovascular disorders (CVD) (p = .00044), while for EFS four factors were significantly associated with a poor outcome: ECOG< 2, age >70 years, CVD and extranodal disease. In conclusion, CVD significantly impacts outcomes of ABVD-treated advanced eHL patients.

摘要

我们回顾性分析了 2001 年至 2013 年期间在波兰的 PLRG-R9 研究中接受 ABVD/ABVD 样方案治疗的 350 例老年霍奇金淋巴瘤(eHL)患者的长期疾病结局。早期(ES)和晚期(AS)患者的完全缓解率分别为 73%和 61%。9 例 ES 和 56 例 AS 患者死亡。中位随访 36(1-190)个月后,ES 患者的 3 年 EFS 和 OS 分别为 0.74(95%CI:0.63-0.85)和 0.90(95%CI:0.82-0.98);AS 患者分别为 0.51(95%CI:0.44-0.57)和 0.81(95%CI:0.75-0.86)。对于 ES 患者,Cox 回归显示 ECOG <2 和年龄>70 是 OS 和 EFS 不良的预测因素。对于 AS 患者,最能预测 OS 的是心血管疾病(CVD)的存在(p = .00044),而对于 EFS,四个因素与不良预后显著相关:ECOG<2、年龄>70 岁、CVD 和结外疾病。总之,CVD 显著影响 ABVD 治疗的晚期 eHL 患者的结局。

相似文献

1
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group.老年霍奇金淋巴瘤患者:来自波兰淋巴瘤研究组的回顾性多中心分析。
Leuk Lymphoma. 2019 Feb;60(2):341-348. doi: 10.1080/10428194.2018.1482539. Epub 2018 Jul 6.
2
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.基于中期PET/CT对早期和晚期霍奇金淋巴瘤初始治疗进行调整是有益的:一项针对355例患者的前瞻性多中心试验。
Br J Haematol. 2017 Sep;178(5):709-718. doi: 10.1111/bjh.14734. Epub 2017 Jun 7.
3
Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.采用ABVD方案治疗的儿童晚期霍奇金淋巴瘤的结局及生存较差的预测因素:一项对186例患者的多中心研究
Leuk Lymphoma. 2017 Jul;58(7):1617-1623. doi: 10.1080/10428194.2016.1262951. Epub 2016 Dec 6.
4
High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.高危晚期霍奇金淋巴瘤:在中期氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)中快速实现代谢完全缓解的患者中,强化BEACOPP和ABVD联合治疗的影响
Acta Haematol. 2016;135(3):156-61. doi: 10.1159/000441962. Epub 2015 Nov 21.
5
Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.60岁以上经典型霍奇金淋巴瘤患者接受一线ABVD化疗的结局:频繁发生肺部事件提示应限制在老年患者中使用博来霉素。
Br J Haematol. 2015 Jul;170(2):179-84. doi: 10.1111/bjh.13419. Epub 2015 Apr 19.
6
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.早期霍奇金淋巴瘤当代治疗的长期随访:德国霍奇金研究组 HD7、HD8、HD10 和 HD11 试验的更新分析。
J Clin Oncol. 2017 Jun 20;35(18):1999-2007. doi: 10.1200/JCO.2016.70.9410. Epub 2017 Apr 18.
7
[Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].国际预后评分在晚期霍奇金淋巴瘤预后预测中的应用可行性研究
Ai Zheng. 2006 Aug;25(8):1013-8.
8
Hodgkin lymphoma among patients infected with HIV in post-HAART era.高效抗逆转录病毒治疗时代后感染HIV患者中的霍奇金淋巴瘤
Clin Lymphoma Myeloma. 2007 Mar;7(5):364-8. doi: 10.3816/CLM.2007.n.014.
9
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).老年霍奇金淋巴瘤患者中,与标准ABVD方案相比,减低剂量VEPEMB方案的疗效:一项代表意大利淋巴瘤基金会(FIL)开展的随机试验结果
Br J Haematol. 2016 Mar;172(6):879-88. doi: 10.1111/bjh.13904. Epub 2016 Jan 13.
10
[Treatment results of Hodgkin's lymphoma].[霍奇金淋巴瘤的治疗结果]
Medicina (Kaunas). 2009;45(8):615-23.

引用本文的文献

1
Newly Diagnosed Classical Hodgkin Lymphoma: Optimizing Outcomes in a New Therapeutic Era.新诊断的经典型霍奇金淋巴瘤:在新治疗时代优化治疗结果
Hematol Oncol. 2025 Jun;43 Suppl 2(Suppl 2):e70066. doi: 10.1002/hon.70066.
2
Hodgkin lymphoma treatment for older persons in the modern era.现代时代老年人霍奇金淋巴瘤的治疗。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):483-499. doi: 10.1182/hematology.2023000449.
3
Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource-limited country: An observational study.
在资源有限的国家,接受 ABVD 与递增 BEACOPP 方案治疗的成人霍奇金淋巴瘤患者的生存率:一项观察性研究。
Cancer Rep (Hoboken). 2023 Aug;6(8):e1839. doi: 10.1002/cnr2.1839. Epub 2023 May 31.
4
Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades.≥50岁经典型霍奇金淋巴瘤患者的治疗反应、毒性及生存情况:一项单中心二十年经验
Cancer Manag Res. 2022 Jun 7;14:1911-1921. doi: 10.2147/CMAR.S363235. eCollection 2022.
5
Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.开发和验证一种预测模型,用于预测接受高强度化疗的老年霍奇金淋巴瘤患者的 1 年死亡率。
J Geriatr Oncol. 2021 Nov;12(8):1233-1239. doi: 10.1016/j.jgo.2021.07.003. Epub 2021 Jul 28.
6
Management of older Hodgkin lymphoma patients.老年霍奇金淋巴瘤患者的管理。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):233-242. doi: 10.1182/hematology.2019000028.